Fed. Circ. Affirms Merck Win In Vytorin, Zetia Patent Case

Law360, New York (February 7, 2013, 6:30 PM EST) -- The Federal Circuit ruled Thursday that a Merck & Co. Inc. unit can enforce a patent for an active ingredient in the cholesterol drugs Vytorin and Zetia, snuffing out generic-drug maker Mylan Inc.'s challenge to the patent's validity.

A three-judge Federal Circuit panel affirmed a district court's ruling that found Merck Sharp & Dohme Corp.'s U.S. Patent Number RE42,461 was both valid and enforceable, according to a two-page per curiam order. The Federal Circuit's order comes just two days after the two sides squared off at...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.